QoL up, costs down with experimental LHRH regimen

October 1, 2002

Orlando, FL-Using serum testosterone levels rather than labelguidelines to re-dose patients on luteinizing hormone-releasing hormone(LHRH) agonist depot therapy can substantially reduce treatment costs andimprove a patient's quality of life, according to researchers at Case WesternReserve University, Cleveland.

Related Content:

Drug Therapy